IP Library Granted Patent US 10,159,751
Granted Patent B2
US 10,159,751 · App. 15/792,242 · Granted Dec 25, 2018

ExPEC glycoconjugate vaccine formulations

Inventors: Olga Labovitiadi (Oegstgeest, NL); Wouter Frank Tonnis (Berlin, DE); Francesco Doro (Siena, IT); Janik Adriaansen (The Hague, NL)
Assignee: JANSSEN PHARMACEUTICALS, INC.
A61K47/646A61K39/0258A61K47/02A61K47/20A61K47/26A61K47/6415A61K47/65C08B37/0063A61K2039/55511A61K2039/55583A61K2039/6037A61K2039/6087A61K2039/70A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,159,751
App. No.
15/792,242
Granted
Dec 25, 2018
Kind
B2
Abstract

Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing E. coli antigen polysaccharide covalently bound to a exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are described.

Claims (37)

1. An immunogenic composition comprising:

a. an E. coli 025B antigen polysaccharide, an E. coli O1A antigen polysaccharide, an E. coli 02 antigen polysaccharide, and an E. coli O6A antigen polysaccharide, wherein each antigen polysaccharide is independently covalently bound to an exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein;

b. 3% to 8% (w/v) sorbitol;

c. 5 to 15 mM methionine;

d. 5 to 20 mM phosphate buffer comprising potassium phosphate and sodium phosphate at a pH of 6.5 to 7.5; and

e. 0.01% to 0.2% (w/v) surfactant.

2. The immunogenic composition of claim 1 , wherein the concentration of sorbitol is 5% (w/v).

3. The immunogenic composition of claim 1 , wherein the concentration of methionine is 10 mM.

4. The immunogenic composition of claim 1 , wherein the concentration of the phosphate buffer is 10 mM, and the pH of the phosphate buffer is 7.0.

5. The immunogenic composition of claim 1 , wherein the surfactant is a non-ionic surfactant.

6. The immunogenic composition of claim 5 , wherein the surfactant is polysorbate 80 (PS80).

7. An immunogenic composition consisting of:

a. an E. coli 025B antigen polysaccharide, an E. coli O1A antigen polysaccharide, an E. coli 02 antigen polysaccharide, and an E. coli O6A antigen polysaccharide, wherein each antigen polysaccharide is independently covalently bound to an exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein;

b. 5% (w/v) sorbitol;

c. 10 mM methionine;

d. 10 mM phosphate buffer comprising KH 2 PO 4 and Na 2 HPO 4 at a pH of 7.0;

e. 0.02% (w/v) polysorbate 80 (PS80); and

f. water.

8. The immunogenic composition of claim 1 , which is stable for at least 6 months when stored at a temperature of 2-8° C.

9. The immunogenic composition of claim 1 , wherein the concentration for each 0-antigen polysaccharide is about 1 to 200 μg/mL.

10. A method for stably maintaining a liquid immunogenic composition comprising an E. coli O-antigen covalently coupled to an EPA carrier protein, the method comprising storing a composition according to claim 1 at a temperature of 2-8° C. for at least 6 months.

11. The immunogenic composition of claim 7 , wherein the concentration for each 0-antigen polysaccharide is about 1 to 200 μg/mL, and the immunogenic composition is stable for at least 6 months when stored at a temperature of 2-8° C.

12. The immunogenic composition of claim 1 , wherein the surfactant is selected from the group consisting of poloxamer 188, polysorbate 20 (PS20), and polysorbate 80 (PS801.

13. The immunogenic composition of claim 6 , wherein the concentration of PS80 is 0.02% (w/v).

14. A method for stably maintaining a liquid immunogenic composition comprising an E. coli O-antigen covalently coupled to an EPA carrier protein, the method comprising storing a composition according to claim 7 at a temperature of 2-8° C. for at least 6 months.

15. An immunogenic composition comprising:

a. an E. coli 025B antigen polysaccharide, wherein the antigen polysaccharide is covalently bound to an exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein;

b. 3% to 8% (w/v) sorbitol;

c. 5 to 15 mM methionine;

d. 5 to 20 mM phosphate buffer comprising potassium phosphate and sodium phosphate at a pH of 6.5 to 7.5; and

e. 0.01% to 0.2% (w/v) surfactant,

wherein the immunogenic composition is stable for at least 6 months when stored at a temperature of 2-8° C.

16. The immunogenic composition of claim 15 , wherein the concentration of sorbitol is 5% (w/v).

17. The immunogenic composition of claim 15 , wherein the concentration of methionine is 10 mM.

18. The immunogenic composition of claim 15 , wherein the concentration of the phosphate buffer is 10 mM, and the pH of the phosphate buffer is 7.0.

19. The immunogenic composition of claim 15 , wherein the surfactant is a non-ionic surfactant selected from the group consisting of poloxamer 188, polysorbate 20 (PS20), and polysorbate 80 (PS80).

20. The immunogenic composition of claim 15 , wherein the surfactant is polysorbate 80 (PS80) and the concentration of PS80 is 0.02% (w/v).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: LABOVITIADI, OLGA; TONNIS, WOUTER FRANK; DORO, FRANCESCO; ADRIAANSEN, JANIK
To: JANSSEN VACCINES & PREVENTION B.V.
Reel/Frame 044363/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: JANSSEN VACCINES & PREVENTION B.V.
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 044363/0371 →
Priority Claims (1)
EP 16195256 · Oct 24, 2016 · regional
Continuity (1)
Related Publication 20180110870A1 · Apr 26, 2018
Cited By (4)
US 12,214,029 US 12,233,118 US 12,233,121 US 12,274,742